Alkermes Spins Off Oncology Business with $275M to Focus on Neuroscience

cafead

Administrator
Staff member
  • cafead   Nov 15, 2023 at 12:12: PM
via Alkermes on Wednesday announced that it has completed the spinoff of its oncology business to become a pure-play neuroscience company. Mural Oncology will begin trading on the Nasdaq starting Thursday, with Alkermes shareholders receiving a share of Mural for every 10 shares of Alkermes.

article source